CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia

Affiliations

Comment

Roland Meisel. N Engl J Med. 2021.

. 2021 Jun 10;384(23):e91.

doi: 10.1056/NEJMc2103481.

¹ Heinrich Heine University, Duesseldorf, Germany meisel@med.uni-duesseldorf.de.

No abstract available

Comment in

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. Reply.
Frangoul H, Ho TW, Corbacioglu S. Frangoul H, et al. N Engl J Med. 2021 Jun 10;384(23):e91. doi: 10.1056/NEJMc2103481. N Engl J Med. 2021. PMID: 34107197 No abstract available.

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, Foell J, de la Fuente J, Grupp S, Handgretinger R, Ho TW, Kattamis A, Kernytsky A, Lekstrom-Himes J, Li AM, Locatelli F, Mapara MY, de Montalembert M, Rondelli D, Sharma A, Sheth S, Soni S, Steinberg MH, Wall D, Yen A, Corbacioglu S. Frangoul H, et al. N Engl J Med. 2021 Jan 21;384(3):252-260. doi: 10.1056/NEJMoa2031054. Epub 2020 Dec 5. N Engl J Med. 2021. PMID: 33283989 Clinical Trial.